Recent Updates
Recently added Catalysts
ACET Positive Sentiment Score: 70/100

Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference

Tuesday, July 21, 2026 1 min read
Key Takeaway: Adicet Bio, a clinical-stage biotechnology company, announced its participation in the Canaccord Genuity 46th Annual Growth Conference. CEO Chen Schor will engage in a fireside chat during the event scheduled for August 11-13, 2026, in Boston. This opportunity highlights the company's focus on developing allogeneic gamma delta T cell therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Adicet Bio is actively participating in a prominent industry conference.
  • The event provides a platform for CEO Chen Schor to share insights.
  • Focus on innovative therapies for autoimmune diseases and cancer.

Full Press Release Details

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston.Details of the event are as follows:Date: Tuesday, August 11, 2026Time: 10:30

Frequently Asked Questions

What is the date of the Canaccord Genuity Conference?

The conference will be held from August 11-13, 2026.

Who will represent Adicet Bio at the conference?

Chen Schor, the President and CEO, will participate.

What is the focus of Adicet Bio's therapies?

Adicet Bio focuses on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.

Tags: ACET Viatris Investor Conferences Healthcare Adicet Bio Canaccord Genuity growth conference Chen Schor
Last updated: Jul 21, 2026